Glycoengineered humanized type II anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct non-complement cell death, aiming to reduce autoantibody production and immune complex formation; administered 1 g IV on day 1 and day 15, repeated at month 6.
Glycoengineered humanized type II anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct non-complement-mediated cell death, reducing autoantibody production and immune complex formation.
YES
DIRECT
Obinutuzumab binds CD20 on B cells and triggers killing via enhanced Fc-mediated ADCC/ADCP by NK cells/macrophages and induces direct, non–complement-mediated cell death (type II antibody).
Therapeutic DNA plasmid vaccine targeting HPV-16/18 for cervical HSIL; delivered intramuscularly with electroporation to enhance plasmid uptake and antigen expression, inducing HPV-specific CD8+ and CD4+ T-cell responses to clear infected dysplastic cervical epithelial cells.
Plasmid DNA encoding HPV-16/18 antigens is delivered intramuscularly with electroporation to enhance cellular uptake and expression; the expressed antigens are presented via MHC I/II to induce HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that eliminate HPV-16/18–infected dysplastic cervical epithelial cells.
YES
INDIRECT
The DNA vaccine elicits HPV-16–specific CD8+ T cells that recognize HPV-16 peptides on MHC I of infected epithelial cells and kill them via perforin/granzyme-mediated cytolysis (with CD4+ T-cell help).
Therapeutic DNA plasmid vaccine targeting HPV-16/18 for cervical HSIL; delivered intramuscularly with electroporation to enhance plasmid uptake and antigen expression, inducing HPV-specific CD8+ and CD4+ T-cell responses to clear infected dysplastic cervical epithelial cells.
Plasmid DNA encoding HPV-16/18 antigens is delivered intramuscularly with electroporation to enhance cellular uptake and expression; the expressed antigens are presented via MHC I/II to induce HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that eliminate HPV-16/18–infected dysplastic cervical epithelial cells.
YES
INDIRECT
The DNA vaccine elicits HPV-18–specific CD8+ T cells that recognize HPV-18 peptides on MHC I of infected epithelial cells and kill them via perforin/granzyme (and Fas–FasL) pathways.
An autologous, gene-modified T-cell therapy in which a patient’s peripheral blood T cells are engineered to express a CD19-specific chimeric antigen receptor (anti-CD19 scFv). CAR engagement enables MHC-independent recognition and activation of T-cell effector functions (cytotoxic killing and cytokine release), leading to depletion of CD19+ leukemic and normal B cells in CD19+ B-ALL.
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor bind CD19 on B cells and trigger MHC-independent T-cell activation, cytotoxic killing, and cytokine release, resulting in depletion of CD19+ leukemic and normal B cells.
YES
DIRECT
CD19 CAR-T cells bind CD19 on target B cells, triggering MHC-independent T-cell activation and cytolysis via perforin/granzyme (and Fas/FasL) pathways, leading to depletion of CD19+ cells.
An anti-c-Met antibody–drug conjugate (ADC) that binds MET (c-Met) on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload causing DNA damage and cell death; disrupts MET-driven signaling.
Monoclonal antibody targets MET (c-Met) on tumor cells; after binding and internalization, releases a topoisomerase I inhibitor payload that induces DNA damage and cell death while disrupting MET-driven signaling.
YES
DIRECT
ADC binds MET on target cells, is internalized, and releases a topoisomerase I inhibitor payload that causes DNA damage leading to apoptosis/cell death.